U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Sitagliptin (marketed as Januvia and Janumet) Information
  1. Drug Safety and Availability

Sitagliptin (marketed as Januvia and Janumet) Information

Sitagliptin (marketed as Januvia and Janumet) Information

Sitagliptin, the first in a new class of diabetic drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 


To report any unexpected adverse or serious events associated with the use of this drug, please contact the FDA MedWatch program and complete a form using the information at the bottom of the page.

Related Information